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Abstract 
Here, we wish to highlight the genetic exchange and epigenetic interactions between EBV and its 
host. Epstein-Barr virus (EBV) is associated with diverse lymphoid and epithelial malignancies. Their 
molecular pathogenesis is accompanied by epigenetic alterations which are distinct for each of them. 
While lymphoblastoid cell lines (LCLs) derived from B cells transformed by EBV in vitro are 
characterized by a massive demethylation and euchromatinization of the viral and cellular genomes, 
the primarily malignant lymphoid tumour Burkitt’s lymphoma (BL) and the epithelial tumours 
nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBVaGC) are characterized by 
hypermethylation of a multitude of cellular tumour suppressor gene loci and of the viral genomes. In 
some cases, the viral latency and oncoproteins including the latent membrane proteins LMP1 and 
LMP2A and several nuclear antigens (EBNAs) affect the level of cellular DNA methyltansferases or 
interact with the histone modifying machinery. Specific molecular mechanisms of the epigenetic 
dialogue between virus and host cell remain to be elucidated. 
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Epstein-Barr virus – the first human tumour virus 
Epstein-Barr virus (EBV), the proto-typical gamma-herpesvirus infecting humans, has been discovered 
50 years ago in cultured Burkitt’s lymphoma (BL) cells (Epstein et al., 1964). EBV physiologically 
homes to memory B cells, a property which is reflected in the genus name Lymphocryptovirus for 
gamma-herpesviruses which “hide in lymphoid cells”. EBV is the causative agent of infectious 
mononucleosis, and was the first known human tumour virus. In addition to BL, an endemic 
childhood tumour mainly of equatorial Africa, EBV plays a role in the origin or progression of other 
primarily malignant B cell tumours, such as Hodgkin lymphoma, and diverse AIDS-associated 
lymphomas including lymphomas of the central nervous system. A profound failure of T cell 
surveillance may allow early-onset post-transplant lymphoproliferative disorder (PTLD) which may be 
overcome upon a timely onset of T cell control, but may turn malignant if growing uncontrolled for 
too long a time span. 
In the first decade of EBV research, EBV was considered a purely lymphotropic virus. Finding viral DNA 
in cellular DNA from biopsies of anaplastic carcinomas of the nasopharynx (NPC) by DNA 
hybridization did not change that general view, because NPC as a lymphoepithelial tumour contains a 
great many of infiltrating lymphocytes (zur Hausen et al., 1970). Localizing the virus specifically to the 
malignant epithelial cells first established EBV infection of non-lymphatic cells and paved the way for 
the novel concept of EBV as an epithelial tumour virus (Wolf et al., 1973). NPC is an endemic tumour 
with a strong preference for South East Asia, especially Guangdong and Hong Kong, with an incidence 
rate of 20 to 30 cases per 100.000 persons per year, and virtually 100% of nonkeratinizing and 
undifferentiated NPCs are EBV-associated. Almost two decades later on, the association of EBV with 
gastric carcinomas (EBVaGC) was established, too (Burke et al., 1990;Shibata et al., 1991). Contrary to 
the endemic tumour NPC, about 10% of the worldwide sporadic tumour gastric carcinoma (GC) are 
associated with EBV infection. Among gastric remnant carcinomas approximately 30% and among 
lymphoepithelioma-like GCs, approximately 80% are EBV-associated. Altogether, EBVaGC with an 
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estimated more than 80.000 cases per year is probably the most frequent EBV-associated malignancy 
worldwide (reviewed in Niller et al., 2014a;Niller et al., 2014b). Beyond the B cell lineage, EBV 
infection is currently associated with T cell lymphomas, epithelial tumours, and rarely with 
leiomyosarcoma, a neoplasm of mesodermal origin (McClain et al., 1995). Furthermore, the risk of 
autoimmune disease, including multiple sclerosis, is significantly increased after primary EBV-
infection, and even more so after symptomatic primary infection, i.e. mononucleosis (Niller et al., 
2008). 
 
Pathogenesis of EBV-associated tumours 
The spectacular ability of EBV to transform and immortalize B cells dominated the first four decades 
of EBV research and tumour virology. General view was that the EBV-transformed cell was the origin 
of the endemic BL cell, too, although a fundamental difference of the epidemiology and pathogenesis 
between LCL-like tumours on one side (early onset PTLD), and of primarily malignant EBV-associated 
lymphomas on the other side (endemic BL) became evident. Early onset PTLD originate under 
conditions of severe immune suppression and depend on viral transforming functions, including 
Epstein-Barr virus nuclear antigens (EBNAs) and latent membrane proteins (LMPs) that are expressed 
both in PTLDs in vivo and in LCLs immortalized in vitro. On the other hand, BL and Hodgkin lymphoma 
originate under conditions of hyperstimulation of the lymphoid germinal center reaction, and they do 
not depend on EBNA2 which the vast majority of them do not express (Klein, 1987;Lenoir and 
Bornkamm, 1987), (Table 1). In this context, it is important to distinguish between morphological and 
oncogenic transformation (Niller et al., 2011). Our discovery of a binding site for the oncoprotein c-
Myc in the central locus control region of the EBV genome suggested that the molecular pathogenesis 
of endemic BL does not depend on a previous EBNA2-transformed state of the B-cell, but mostly on a 
dysbalance of pro-and anti-apoptotic functions in consequence of myc-translocation, a molecular 
accident in a virus infected B cell undergoing the germinal center reaction (Niller et al., 2003). The 
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need to counter-balance the pro-apoptotic force of translocated c-Myc through anti-apoptotic 
functions, either encoded by the viral genome or induced by virus infection, in order for a BL to 
emerge has recently been re-emphasized (Mbulaiteye, 2013;Westhoff Smith and Sugden, 2013). Our 
differential pathogenesis model for EBV-associated lymphomas was controversial at first (Rossi and 
Bonetti, 2004;Thorley-Lawson, 2004;reviewed in Niller et al., 2012), but has now gained strong 
support by recent large-scale epigenomic analyses of LCLs and tumour cells (see below). Thus, finding 
the binding site for the oncoprotein c-Myc in the locus control region of EBV caused a conceptual 
shift away from the morphologically transformed cell and has turned out as a heuristic discovery 
(Niller et al., 2003). 
 
Genetic exchange between herpesviruses and host cells 
Homology between herpesviral and human genes is now a common theme which was first 
highlighted by the finding of a gene for a functional thymidylate synthase (TS) in the genome of 
herpesvirus saimiri with an extremely high homology of 70% identical amino acids with the human TS 
gene. Various parameters suggested that the TS gene had been acquired in virus evolution by an 
ancestral herpesvirus from the cellular genome (Bodemer et al., 1986;Honess et al., 1986). The 
exchange of human and viral genes, and in the case of human herpesvirus 6 (HHV-6) the invasion of 
an entire herpesviral genome into the human germ line (Daibata et al., 1999) in about 0.8% of 
humans, must have happened on numerous occasions in evolutionary time. In the case of EBV, the 
intimate evolutionary relationship of virus and host cell is emphasized by the presence of several viral 
genes with sequence homology to cellular genes, i.e. BHRF1 and BALF1, two anti-apoptotic BCL2 
homologues, BILF1, coding for a constitutively active G protein-coupled receptor (GPCR) homologue, 
and BCRF1, an IL-10 (interleukin 10) gene homologue. The BCRF1 protein appears to be a functional 
homologue of IL-10, an immune suppressive cytokine secreted by Th2 cells with a sequence identity 
of about 70% (Hsu et al., 1990). The sequence homologies of the other three viral peptides are of 
lower degree than that. BHRF1 carries a 25% identity of an 150 amino acid C-terminal portion with 
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the anti-apoptotic cellular protein BCL2 (Cleary et al., 1986). BALF1 shows homology at a similar 
degree in functionally important domains to its cellular counterparts BCL2 and BCLX (Marshall et al., 
1999). BILF1 carries a homology of around 20% with the human chemokine receptor CXCR3A (Davis-
Poynter and Farrell, 1996;Beisser et al., 2005;Paulsen et al., 2005). EBV-associated carcinoma cells 
express BARF1, identified initially as a lytic cycle protein that binds to hCSF-1 (human colony 
stimulating factor 1) as a viral decoy receptor, although its crystal structure is most closely related to 
CD80, a co-stimulatory molecule of antigen presenting cells (Seto et al., 2005;Tarbouriech et al., 
2006;Elegheert et al., 2012). 
Herpesviral DNA binding proteins ICP8 of HSV1 and BALF2 of EBV, and additional homologous 
proteins of human herpesviruses which are required for viral replication belong to a class of 
“DDE/RNAse H-like fold-family” nucleases, together with the recombination activating gene (RAG) 1 
protein, essential for V(D)J recombination, and the Argonaute protein of the RNA induced silencing 
complex (RISC). For ICP8 of HSV, divalent cation binding of the DDE-site was actually shown to be 
functional and required for viral replication (Bryant et al., 2012). Furthermore, inhibitors of HIV 
integrase, another RNAse H-fold protein, inhibited the replication of viruses from all herpesvirus 
genera, too (Yan et al., 2014). Based on a co-regulatory transcriptional network for both RAG-1 and 
RAG-2, and the genes for herpesviral DNA-binding proteins, and based on signature sequence 
homologies between V(D)J recombination sites and the viral terminal repeats, an evolutionary 
relationship between the RAG recombinase and herpesviral DNA binding proteins was proposed. The 
RAG locus may have originally been introduced to host cells by a primordial herpesvirus (Dreyfus, 
2009). We found a striking co-linearity of structural and functional elements between the cellular 
immunoglobulin gene loci and the left part of the EBV genome. Therefore, although speculative, we 
agree with the view that, in the case of the RAG genes, the appearance of the adaptive immune 
system may have been dependent on a primordial herpesvirus genome and, in the case of the B cell, 
may have developed further as consequence of an evolutionary ping-pong game between EBV and 
the host cell (Niller et al., 2004). 
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Epigenetic interactions between EBV and its host cells 
EBV infects both B lymphocytes and epithelial cells in vivo. It enters B cells after binding to CD21, a 
cell surface molecule absent from epithelial cells. However, EBV infected B cells are capable to 
transfer the virus to epithelial cells lacking the EBV receptor. Both B cells and epithelial cells can 
support productive (lytic) EBV replication when all of the proteins and nontranslated RNAs encoded 
by the viral genome are expressed in a sequential order. EBV also causes latent infections, typically in 
resting memory B cells and in various neoplastic cells that usually carry circular, double stranded viral 
genomes. During latency, only a restricted set of EBV promoters is active. The activity of latent EBV 
promoters depends on the phenotype of host cells, and it is controlled by the epigenetic regulatory 
machinery. Based on the epigenetic marks deposited on the viral chromatin by the cellular epigenetic 
machinery one can distinguish between viral epigenotypes that are associated with unique patterns 
of viral gene expression (reviewed in Minarovits, 2006). In parallel, certain latent EBV proteins 
characteristic for the major cell types carrying latent EBV genomes act as epigenetic regulators 
themselves: they alter the cellular epigenotype and gene expression pattern and may contribute to 
the development of malignant tumours. Thus, the situation is similar to an „epigenetic dialogue”, 
indeed. Typical examples of EBV latency types are summarized in Table 1, based on the nomenclature 
suggested by Klein et al., 2013 (Klein et al., 2013), see also (Laytragoon-Lewin et al., 1995;Niller et al., 
2012). 
 
Epigenetic control of EBV latency promoters 
The epigenetic regulatory mechanisms of host cells not only control the preservation of cell type 
specific gene expression patterns from cell generation to cell generation, but ensure the maintenance 
of host cell-dependent usage of latent EBV promoters as well. Epigenetic regulation is based on 
writing, reading and erasing epigenetic marks on chromatin as well as on protein-DNA interactions 
that are stable even in mitotic, highly condensed chromatin (reviewed in Gopalakrishnan et al., 
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2008;Zaret et al., 2008;Sharma et al., 2010;Blomen and Boonstra, 2011). Euchromatic marks favour 
transcription whereas heterochromatic marks are associated with a more condensed chromatin 
structure that usually represses promoter activity. 
DNA methylation is involved in silencing of most latent EBV promoters. It is well documented that the 
alternative promoters Wp and Cp, where transcripts coding for six Epstein-Barr virus nuclear antigens 
(EBNAs) are initiated can be switched off by CpG methylation. In addition, LMP1p and LMP2Ap, the 
promoters for latent membrane protein 1 and 2A transcripts are silenced by the activity of cellular 
DNA methyltransferases, too. DNA methylation does not play a role, however, in switching off Qp, an 
alternative promoter for EBNA1 transcripts (reviewed in Li and Minarovits, 2003;Niller et al., 2012). 
One may speculate, that EBNA2, the major transactivator protein encoded by the EBV genome that 
interacts with both histone acetyltransferases and histone deacetylases, (reviewed in Niller et al., 
2009) may activate key cellular genes mediating genome-wide demethylation in LCLs. Acetylation of 
histone H3 and histone H4 molecules and di- or trimethylation of lysine 4 of histone H3 (H3K4me2 or 
H3K4me3) are euchromatic marks frequently associated with active Cp, Qp, LMP1p and LMP2Ap 
(reviewed in Niller et al., 2012;Arvey et al., 2013). In principle, complexes formed by Polycomb and 
Trithorax group proteins that modify histone tails could also play a role in the regulation of latent EBV 
promoters but there are no data supporting such a mechanism. In contrast, Polycomb group protein 
EZH2 was observed to leave a heterochromatic histone mark (H3k27me3) at early lytic promoters of 
EBV that are silent during latency, and chromatin immunoprecipitation proved the association of the 
EZH2 methyltransferase with this class of viral promoters in the BL cell line Raji (Woellmer et al., 
2012). The immediate early promoter Zp, where transcripts for the lytic cycle initiating BZLF1 protein 
are initiated was also found to be repressed by H3k27me3 but also by H4K20me3 in Raji cells (Murata 
et al., 2012). 
Pioneer transcription factors and variant histone molecules that bind to repressive chromatin areas 
and mark the genes to be activated have not been implicated in the control of EBV latency. Chromatin 
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loops formed by binding of insulator proteins to EBV episomes may play a role, however, in the 
epigenetic regulation of the latency promoters Cp and Qp (Tempera et al., 2011). 
 
EBV-encoded oncoproteins as epigenetic regulators 
The methylation patterns of nasopharyngeal carcinoma cells and EBVaGC cells differ from their 
normal counterparts: these neoplastic cells regularly carry hypermethylated genomic regions with 
silenced cellular promoters (Iizasa et al., 2012;Lo et al., 2012). Focal hypermethylations frequently 
inactivate tumour suppressor genes and may contribute to carcinogenesis and tumour progression. 
Because the EBV encoded transmembrane proteins LMP1 and LMP2A are capable of upregulating the 
cellular DNA methyltransferases DNMT1, DNMT3A and DNMT3B, it was suggested that 
hypermethylation of CpG rich sequences, the so called CpG islands, is mediated by LMP1 or LMP2A in 
EBV-associated carcinomas (reviewed in Niller et al., 2012). LMP1 and LMP2A are expressed in EBV 
positive Hodgkin lymphomas as well. Thus, they may contribute to gene silencing in these neoplasms, 
too. 
It is worthy to note that, similarly to the EBV-associated carcinomas, LCLs established by in vitro EBV-
infection of B cells also express LMP1 and LMP2A that could potentially upregulate DNA 
methyltransferases. It was observed, however, that the typical epigenetic change in LCLs is a 
widespread demethylation of the B cell methylome affecting one third of all cellular genes and 2.18 
GB of the genome (Hansen et al., 2014). The mechanism of demethylation remains to be established. 
Furthermore, the EBV episomes carried by LCLs are also hypomethylated, in contrast to the overall 
hypermethylation of EBV genomes in latency type I BL lines, BL biopsies and EBV-associated 
carcinomas (Minarovits et al., 1991;Fernandez et al., 2009). One may speculate, that EBNA2, the 
major transactivator protein encoded by the EBV genome that interacts with both histone 
acetyltransferases and histone deacetylases (reviewed in Niller et al., 2009) may activate key cellular 
genes mediating genome-wide demethylation of both cellular and viral DNA in LCLs. The viral 
oncoproteins EBNA3A and EBNA3C expressed during in vitro immortalization of B cells silence distinct 
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cellular tumour suppressor genes by depositing a heterochromatic histone mark via the Polycomb 
repressor complex PCR2 (reviewed in Allday, 2013). The dominant change in EBV immortalized B cells 
seems to be, however, a genome-wide decrease and redistribution of heterochromatic marks 
(Hernando et al., 2014). The EBV latency products eliciting the reprogramming of the host cell 
epigenome in LCLs remain to be elucidated. Contrary to LCLs, primarily malignant lymphomas, i.e. BL 
and other lymphomas, are characterized not by a massive and wide-spread hypomethylation, but by 
a local hypermethylation of selected genomic loci (Martin-Subero et al., 2009a;Martin-Subero et al., 
2009b;Kreck et al., 2013; reviewed in Niller et al., 2014b). 
In contrast to BL tumours, in which hypermethylated loci are strongly enriched for polycomb 
repressive complex (PRC) target genes of embryonic stem cells, hypermethylated genes in EBVaGC are 
not enriched for PRC targets (Martin-Subero et al., 2009a;Matsusaka et al., 2011). Contrary to 
Helicobacter pylori-associated GC, EBVaGC does not emerge from an “epigenetic field” in the gastric 
mucosa (Matsusaka et al., 2011;Niller et al., 2014a). Thus, EBV-associated epigenetic changes may 
quite quickly set the stage for malignancy (Au et al., 2005;Niller et al., 2014a). Notably, even transient 
EBV infection of epithelial cells leaves permanent epigenetic scars indicating past infection (Queen et 
al., 2013;Birdwell et al., 2014). 
Although there are no data as to the interaction of host cell-encoded pioneer transcription factors 
and the EBV genome, certain viral proteins that bind to both viral and cellular DNA and remain 
associated with mitotic chromosomes may act as pioneer transcription factors. EBNA1, a nuclear 
protein expressed in all EBV latency types is a putative pioneer factor functionally resembling 
transcription factors of the FoxA family that act as epigenetic regulators controlling important 
developmental processes (Niller and Minarovits, 2012). EBNA1 was shown to bind to different sets of 
cellular promoters in cell lines of epithelial and lymphoid origin, and upregulation as well as 
downregulation of distinct gene batteries was observed (Canaan et al., 2009). In the BL cell line Raji, 
EBNA1 was shown to interact with a large number of cellular genes as well as LINE elements, and high 
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affinity EBNA binding sites were observed in a repetitive sequence in chromosome 11 (Lu et al., 
2010).  
BZLF1, an immediate-early EBV protein initiating productive viral replication that preferentially binds 
methylated DNA sequences was also suggested to act as a pioneer transcription factor (Woellmer et 
al., 2012). BZLF1 is expressed not only during the lytic cycle but transiently also during the 
establishment of latent infection of B cells in vitro (Kalla and Hammerschmidt, 2012). Because BZLF1 
can bind to cellular promoters (Lan et al., 2013) and elicit epigenetic alterations (Woellmer et al., 
2012), an “epigenetic dialogue” between the latent EBV genomes and the host cell genome may 
occur, indeed: transient BZLF1 expression may change the cellular epigenotype followed by silencing 
of the BZLF1 promoter through the cellular epigenetic machinery. In parallel, EBV encoded epigenetic 
regulators may leave their marks on the cellular epigenotype in a next phase of EBV-mediated B cell 
immortalization. 
In conclusion, on an evolutionary time scale a genetic exchange between herpesviruses and their 
hosts is evident. Beginning with the early steps of viral infection, epigenetic interactions between 
virus and host cell are taking place. The multi-tiered epigenetic dialogue between EBV and its host 
needs to be elucidated in greater molecular detail in order to understand the diverse outcomes of 
infection. 
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Table 1. Host cell-dependent expression of latent Epstein-Barr virus proteins. Key viral latency 
proteins or so-called oncoproteins are differentially expressed in EBV-associated malignancies and 
transformed cell lines. Depending on the specific viral gene expression patterns, specific viral latency 
classes are defined. 
 
Protein      Cell type and latency type 
    BL  NPC  CLL  LCL 
    Type I  Type IIa Type IIb Type III 
EBNA1    +  +  +  + 
EBNA2    -  -  +  +  
LMP1    -  +/-  -  + 
LMP2A    -  +  +  + 
BARF1     -  +  -  -  
 
Abbreviations 
BL: Burkitt’s lymphoma, NPC: nasopharyngeal carcinoma, CLL: chronic lymphocytik leukaemia, LCL: 
lymphoblastoid cell line, EBNA: Epstein-Barr virus nuclear antigen, LMP: latent membrane protein, 
BARF1: BamHI A rightward frame 1. 
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